BJ-B11 is a novel Hsp90 inhibitor that reportedly exhibits antitumor activity in myeloid leukemia and esophageal carcinoma (15, 16); however, its antitumor activity in breast cancer has not yet been investigated. This evidence concerns the gene HSP90AA1 and breast cancer.